题名

成本效益分析探討子宮頸癌、口腔癌篩檢策略：文獻系統回顧

并列篇名

Cost- Effectiveness Analysis on Screening Strategies for Cervical Cancer and Oral Cavity Cancer: A Systematic Review

作者

江向才(Hsiang-Tsai Chiang)；杜俊毅(Chun-Yi Tu)

关键词

子宮頸癌 ； 口腔癌 ； 篩檢策略 ； 成本效益分析 ； 文獻系統回顧 ； Cervical Cancer ； Oral Cavity Cancer ； Screening Strategies ； Cost- effectiveness Analysis ； A Systematic Review

期刊名称

台灣健康照顧研究學刊

卷期/出版年月

20期（2019 / 07 / 01）

页次

1 - 35

内容语文

繁體中文
中文摘要

台灣無口腔癌篩檢成本效益研究，子宮頸抹片檢查降低死亡率及篩檢率呈現停滯，人類乳突病毒（HPV）疫苗接種預防及治療子宮頸癌、口腔癌的防治策略已成國際趨勢。本研究以文獻系統回顧分析全球二十國家學者子宮頸癌篩檢22篇、口腔癌篩檢6篇，結果發現子宮頸癌篩檢具成本效益共20篇；口腔癌篩檢具成本效果共6篇，表明子宮頸抹片檢查仍是全球子宮頸癌最具成本效益篩檢策略、HPV細胞學檢測具成本效益是醫療資源貧乏國家替代方案，子宮頸癌HPV疫苗接種具成本效益是未來防治方向；口腔癌黏膜篩檢雖有爭議但研究結果具成本效益，表明有計劃執行年度子宮頸癌及口腔癌篩檢策略具成本效益，我們支持台灣子宮頸癌及口腔癌篩檢國家防治策略值得持續推廣。現今如何減輕民眾對篩檢的畏懼及增加意願來提高篩檢率，HPV細胞學檢測可考慮放寬篩檢對象及HPV疫苗接種防治擴大推廣年輕女孩及男孩HPV疫苗防治子宮頸癌及口腔癌計劃可提供未來政策參考。
英文摘要

There is no cost-effectiveness study for oral cavity cancer screening in Taiwan. The cervical smear screening to reduce mortality and screening rate shows stagnation. The vaccination prevention of the Human Papilloma Virus (HPV) and the prevention strategy of cervical cancer, oral cancer has become an international trend. This study uses literature review to analyze 22 cervical cancer screenings and 6 oral cancer screenings in 20 countries. The results showed that cervical cancer screening has cost-effective of 20 articles, and oral cancer screening was 6 articles. Shows that cervical smear screening is still the most cost-effective screening strategy for cervical cancer worldwide. The cost-effectiveness of HPV cytology testing is an alternative to poorly resourced medical countries and the cost-effectiveness of cervical cancer HPV vaccination is the future direction of prevention. Oral cancer mucosal screening is controversial but the results are cost-effective. Shows that there are plans to implement annual cervical cancer and oral cancer screening strategies that are cost-effective. We support that Taiwan's cervical cancer and oral cancer screening national control strategy is worth promoting. Today's issues on how to reduce public fear of screening and increase willingness to increase screening rates. HPV cytology testing may consider relaxing screening targets and expanding the promotion of HPV vaccine for young girls and boys to prevent cervical cancer and oral cancer programs can provide future policy reference.
主题分类 醫藥衛生 > 預防保健與衛生學
醫藥衛生 > 社會醫學
参考文献
  1. Wen, C. P.,Cheng, C. W.,Cheng, T. Y.,Tsai, M. K.,Chiang, P. O. H.,Tsai, S. P.,Hsing, Y. I.(2009).Trends in betel quid chewing behavior in Taiwan - Exploring the relationship between betel quid chewing and smoking.Taiwan Journal of Public Health,28(5),407-419.
    連結：
  2. 詹明錦,邱勝康,吳建昌,方啟泰(2013)。人類乳突病毒疫苗接種政策：公共衛生倫理觀點稱。台灣衛誌，4(32)，309-319。
    連結：
  3. Abraham, J. M.(2013).Using microsimulation models to inform U.S. health policy making.Health Services Research,48(2 Pt 2),686-695.
  4. American Cancer Society. (2019). American Cancer Society recommendations for human papillomavirus (HPV) vaccine use to prevent cervical cancer and pre-cancers. Retrieved from http://www.cancer.org/cancer/cancercauses/othercarcinogens/infectiousagents/hpv/acs- recommendations-for-hpv-vaccine-use
  5. Arbyn, M.,Anttila, A.,Jordan J.,Ronco, G.,Schenck, U.,Segnan, N.,von Karsa, L.(2010).European guidelines for quality assurance in cervical cancer screening. Second edition-summary document.Annals of Oncology,21(3),448-458.
  6. Bailey, H. H.,Chuang, L. T.,DuPont, N. C.,Eng, C.,Foxhall, L. E.,Merrill, J. K.,Blanke, C. D.(2016).American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.Journal of Clinical Oncolog,34(15),1803-1812.
  7. Barré, S.,Massetti, M.,Leleu, H.,De Bels, F.(2017).Organized screening for cervical cancer in France: a cost-effectiveness assessment.BMJ open,7(10),e014626.
  8. Bosch, F. X.,Munoz, N.(2002).The viral etiology of cervical cancer.Virus Res,89(2),183-190.
  9. Campos, N. G.,Castle, P. E.,Wright Jr, T. C.,Kim, J. J.(2015).Cervical cancer screening in low‐resource settings: A cost‐effectiveness framework for valuing tradeoffs between test performance and program coverage.International journal of cancer,137(9),2208-2219.
  10. Campos, N. G.,Tsu, V.,Jeronimo, J.,Njama-Meya, D.,Mvundura, M.,Kim, J. J.(2017).Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting.Health Policy and Planning,32(7),956-968.
  11. CASP, U. (2019). Critical Appraisal Skills Program (CASP). Retrieved from https://caspuk.net/casp-tools-checklists/
  12. Chao, A.,Jao, M. S.,Huang, C. C.,Huang, H. J.,Cheng, H. H.,Yang, J. E.,Lai, C. H.(2011).Human papillomavirus genotype in cervical intraepithelial neoplasia grades 2 and 3 of Taiwanese women.Int J Cancer,128(3),653-659.
  13. Chaturvedi, A. K.,Engels, E. A.,Pfeiffer, R. M.,Hernandez, B. Y.,Xiao, W.,Kim, E.,Gillison, M. L.(2011).Human Papilloma virus and Rising Oropharyngeal Cancer Incidence in the United States.Journal of Clinical Oncology,29(32),4294-4301.
  14. de Kok, I. M.,Habbema, J. F.,van Rosmalen, J.,van Ballegooijen, M.(2011).Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness?.European Journal of Cancer,47(3),428-435.
  15. de Villiers, E. M.,Fauquet, C.,Broker, T. R.,Bernard, H. U.,zur Hausen, H.(2004).Classification of papillomaviruses.Virology,324(1),17-27.
  16. Dedhia, R. C.,Smith, K. J.,Johnson, J. T.,Roberts, M.(2011).The cost‐effectiveness of community‐based screening for oral cancer in high‐risk males in the United States: A Markov decision analysis approach.The Laryngoscope,121(5),952-960.
  17. Ezat, S. P.,Aljunid, S.(2010).Comparative cost-effectiveness of HPV vaccines in the prevention of cervical cancer in Malaysia.Asian Pacific Journal of Cancer Prevention: APJCP,11(4),943-951.
  18. Ferlay, J.,Soerjomataram, I.,Dikshit, R.,Eser, S.,Mathers, C.,Rebelo, M.,Bray, F.(2015).Cancer incidence and mortality worldwide: sources, methods, and major patterns in GLOBOCAN 2012.Int J Cancer,136(5),359-386.
  19. Franco, E. L.,Harper, D. M.(2005).Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control.Vaccine,23(17-18),2388-2394.
  20. Frazer, I. H.(2004).Prevention of cervical cancer through papillomavirus vaccination.Nature Reviews Immunology,4(1),46-54.
  21. Ginsberg, G. M.,Edejer, T. T. T.,Lauer, J. A.,Sepulveda, C.(2009).Screening, prevention and treatment of cervical cancer-a global and regional generalized cost-effectiveness analysis.Vaccine,27(43),6060-6079.
  22. Glenny, A. M.,Furness, S.,Worthington, H. V.,Conway, D. I.,Oliver, R.,Clarkson, J. E.,Brocklehurst, P.(2010).Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy.Cochrane Database Syst Rev,12,CD006387.
  23. Guerrero, A. M.,Genuino, A. J.,Santillan, M.,Praditsitthikorn, N.,Chantarastapornchit, V.,Teerawattananon, Y.,Toral, J. A.(2015).A cost-utility analysis of cervical cancer screening and human papillomavirus vaccination in the Philippines.BMC Public Health,15,730.
  24. Hsing, C. Y.,Wong, Y. K.,Wang, C. P.,Wang, C. C.,Jiang, R. S.,Chen, F. J.,Liu, S.A.(2011).Comparison between free flap and pectoralis major pedicled flap for reconstruction in oral cavity cancer patients – a quality of life analysis.Oral Oncol,47(6),522-527.
  25. IARC-International Agency for Research on Cancer (2018). Retired from http://www.who.int/ionizing_radiation/research/iarc/en
  26. Jacobson, J. J.,Epstein, J. B.,Eichmiller, F. C.,Gibson, T. B.,Carls, G. S.,Vogtmann, E.,Murphy, B.(2012).The cost burden of oral, oral pharyngeal, and salivary gland cancers in three groups: commercial insurance, Medicare, and Medicaid.Head & Neck Oncology,4(1),15.
  27. Kaplan, R. M.(1995).Utility assessment for estimating quality-adjusted life years.Valuing health care: Costs, benefits, and effectiveness of pharmaceuticals and other medical technologies
  28. Karnon, J.,Peters, J.,Platt, J.,Chilcott, J.,McGoogan, E.,Brewer, N.(2004).Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.Health Technology Assessment
  29. Ko, M. J.,Kim, J.,Kim, Y.,Lee, Y. J.,Hong, S. R.,Lee, J. K.(2015).Cost-effectiveness analysis of cervical cancer screening strategies based on the Papanicolaou smear test in Korea.Asian Pacific Journal of Cancer Prevention,16(6),2317-2322.
  30. Kosen, S.,Andrijono, A.,Ocviyanti, D.,Indriatmi, W.(2017).The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia.Asian Pacific journal of cancer prevention: APJCP,18(7),2011-2017.
  31. Koutsky, L. A.,Ault, K. A.,Wheeler, C. M.,Brown, D. R.,Barr, E.,Alvarez, F. B.,Jansen, K.U.(2002).A controlled trial of a human papillomavirus type 16 vaccine.N Engl J Med,347(21),1645-1651.
  32. Kulasingam, S. L.,Rajan, R.,St Pierre, Y.,Atwood, C. V.,Myers, E. R.,Franco, E. L.(2009).Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis.BMC Medicine,7(1),69.
  33. Lince-Deroche, N.,Phiri, J.,Michelow, P.,Smith, J. S.,Firnhaber, C.(2015).Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa.PLOS One,10(11),e0141969.
  34. Mahdavi, A.,Monk, B. J.(2005).Vaccines against human papillomavirus and cervical cancer, promises and challenges.Oncologist,10(7),528-538.
  35. McGuigan, J.,Moyer, R.(1986).Managerial Economics.St. Paul:West Publishing Co..
  36. Mo, X.,Gai Tobe, R.,Wang, L.,Liu, X.,Wu, B.,Luo, H.,Nagata, C.,Nakayama, T.(2017).Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.BMC infectious diseases,17(1),502.
  37. Moyer, V. A.(2012).Screening for cervical cancer: U.S. preventive services task force recommendation statement.Annals of internal medicine,156(12),880-891.
  38. Moyer, V. A.(2014).Screening for oral cancer: US Preventive Services Task Force recommendation statement.Annals of internal medicine,160(1),55-60.
  39. Nagler, R. M.(2002).Molecular aspects of oral cancer.Anticancer Research,22(5),2977-2980.
  40. Nahvijou, A.,Daroudi, R.,Tahmasebi, M.,Amouzegar Hashemi, F,Rezaei Hemami, M.,Akbari Sari, A.,Zendehdel, K.(2016).Cost-Effectiveness of Different Cervical Screening Strategies in Islamic Republic of Iran: A Middle-Income Country with a Low Incidence Rate of Cervical Cancer.PLOS One,11(6),e0156705.
  41. Neville, A. M.,Quinn, M. A.(2005).An alternative cost effectiveness analysis of Thin Prep in the Australian setting.The Australian & New Zealand Journal of Obstetrics & Gynaecology,45(4),289-294.
  42. Olsen, J.,Jørgensen, T. R.(2015).Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females.Cost Effectiveness and Resource Allocation,13,4.
  43. Praditsitthikorn, N.,Teerawattananon, Y.,Tantivess, S.,Limwattananon, S.,Riewpaiboon, A.,Chichareon, S.,Tangcharoensathien, V.(2011).Economic evaluation of policy options for prevention and control of cervical cancer in Thailand.Pharmacoeconomics,29(9),781-806.
  44. Pytynia, K.,Dahlstrom, K. R.,Sturgis, E. M.(2014).Epidemiology of HPV-associated oropharyngeal cancer.Oral Oncology,50(5),380-386.
  45. Ranganathan, K.,Devi, M. U.,Joshua, E.,Kirankumar, K.,Saraswathi, T. R.(2004).Oral submucous fibrosis: a case‐control study in Chennai, South India.Journal of oral pathology & medicine,33(5),274-277.
  46. Rashid, R. M.,Ramli, S.,John, J.,Dahlui, M.(2014).Cost effective analysis of recall methods for cervical cancer screening in Selangor-results from a prospective randomized controlled trial.Asian Pacific Journal of Cancer Prevention,15(13),5143-5147.
  47. Sankaranarayanan, R.,Ramadas, K.,Thomas, G.,Muwonge, R.,Thara, S.,Mathew, B.,Trivandrum Oral Cancer Screening Study Group(2005).Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomized controlled trial.The Lancet,365(9475),1927-1933.
  48. Santana, J. C.,Delgado, L.,Miranda, J.,Sánchez, M.(1997).Oral cancer case finding program (OCCFP).Oral Oncology,33(1),10-12.
  49. Siegel, R. L.,Miller, K. D.,Jemal, A.(2016).Global Cancer Statistics.CA Cancer J Clin,66(1),7-30.
  50. Siegel, R.,Ma, J.,Zou, Z.,Jemal, A.(2014).Jemal Cancer statistics.CA Cancer J Clin,64(1),9-29.
  51. Speight, P. M.,Palmer, S.,Moles, D.,Downer, M. C.,Smith, D. H.,Henriksson, M.,Augustovski, F.(2006).The cost-effectiveness of screening for oral cancer in primary care.Health Technology Assessment,10(14),1-144.
  52. Suba, E. J.,Nguyen, C. H.,Nguyen, B. D.,Raab, S. S.(2001).De novo establishment and cost-effectiveness of Papanicolaou cytology screening services in the Socialist Republic of Vietnam.Cancer,91(5),928-939.
  53. Subramanian, S.,Sankaranarayanan, R.,Bapat, B.,Somanathan, T.,Thomas, G.,Mathew, B.,Ramadas, K.(2009).Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India.Bulletin of the World Health Organization,87(3),200-206.
  54. Taylor, L. A.,Sorensen, S.V.,Ray, N. F.,Halpern, M. T.,Harper, D.M.(2000).Costeffectiveness of the conventional Papanicolaou test with a new adjunct to cytological screening for squamous cell carcinoma of the uterine cervix and its precursors.Archives of family medicine,9(8),713-721.
  55. Techakehakij, W.,Feldman, R. D.(2008).Cost-effectiveness of HPV vaccination compared with Pap smear screening on a national scale: a literature review.Vaccine,26(49),6258-6265.
  56. Termrungruanglert, W.,Khemapech, N.,Tantitamit, T.,Sangrajrang, S.,Havanond, P.,Laowahutanont, P.(2017).Cost-effectiveness analysis study of HPV testing as a primary cervical cancer screening in Thailand.Gynecologic Oncology Reports,22,58-63.
  57. van den Akker-van Marle, M. E.,van Ballegooijen, M.,van Oortmarssen, G. J.,Boer, R.,Habbema, J. D. F.(2002).Cost-effectiveness of cervical cancer screening: comparison of screening policies.Journal of the National cancer institute,94(3),193-204.
  58. Vokó, Z.,Túri, G.,Zsólyom, A.(2016).Cost-effectiveness of oral cancer screening in Hungary.Orvosi hetilap,157(29),1161-1170.
  59. Walboomers, J. M.,Jacobs, M. V.,Manos, M. M.,Bosch, F. X.,Kummer, J. A.,Shah, K. V.,Muñoz, N.(1999).Human papillomavirus is a necessary cause of invasive cervical cancer worldwide.J Pathol,189(1),12-19.
  60. World Health Organization(2009).Human papillomavirus vaccines: WHO position paper.Weekly Epidemiological Record,84(15),118-131.
  61. World Health Organization. (2017). Cost effectiveness and strategic planning (WHO-CHOICE). Table: threshold values for intervention cost-effectiveness by region. 2010). Retired from http://www. who. int/choice/costs/CER_levels/en
  62. Xu, H.,Zhao, F. H.,Gao, X. H.,Hu, S. Y.,Chen, J. F.,Liu, Z. H.,Qiao, Y. L.(2013).Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China.Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi,34(4),399-403.
  63. Yabroff, K. R.,Kerner, J. F.,Mandelblatt, J. S.(2000).Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening.Preventive medicine,31(4),429-439.
  64. 王功亮,陳子健(2000)。人乳突病毒與子宮頸癌：致病機轉與其疫苗之發展。台北市醫師公會會刊，44，63-65。
  65. 王美卿(2010)。成功大學護理學系。
  66. 王榮德,游正芬,鍾智文,姚開屏(2000)。廿一世紀之健康照護效性評量：生活品質與生活品質調整後之存活分析。台灣醫學，1(4)，65-74。
  67. 行政院衛生福利部國民健康署（2018）。《預防保健/取自癌症防治》。行政院衛生福利部國民健康署網頁(http://www.hpa.gov.tw/BHPNet/Web/Stat/Statistics.aspxhttps)。
  68. 宋桂容,楊麗瓊,蘇惠文,張怡媛,林小玲(2012)。HPV 自我採檢可否有效提高婦女子宮頸癌篩檢率之實證探討。榮總護理，2(29)，124-130。
  69. 林秀玲(2003)。臺北醫學大學醫務管理學研究所。
  70. 林敬旺(2008)。中國醫藥大學醫務管理學系碩士在職專班。
  71. 孫嘉玲,余逸嫻,林雨潔,吳素綿,涂雅玲,袁淑玉,呂儀君(2005)。多媒體教育課程在嚼檳榔族群對嚼檳榔行為及口腔癌篩檢之成效。元培學報，12，79-90。
  72. 財團法人醫藥品查驗中心（2014）。《醫療科技評估方法學指引》。The ISPOR Global Health Care Systems Road Map 網站(https://tools.ispor.org/PEguidelines/source/HTA_guidelines_Taiwan.pdf)
  73. 梁錦榮(2003)。高雄榮總門診患者對口腔癌認知的研究。中華民國口腔顎面外科學會雜誌，2(14)，97-104。
  74. 陳小梨(2004)。行政院國家科學委員會專題研究計畫成果報告行政院國家科學委員會專題研究計畫成果報告,台北:行政院國家科學委員會。
  75. 劉崇基（2004）。《口腔癌治療》。中華民國口腔顎面外科學會網站(http://www.aoms.org.tw/member/academic/academic03/chapter6.pdf)
  76. 劉惠珊(2012)。臺灣大學流行病學與預防醫學研究所。
  77. 蔡秉磬(2012)。臺北醫學大學醫務管理學研究所。
  78. 藍婷 （2018）。《醫療科技決策分析模型簡介》。財團法人醫藥品查驗中心網頁(http://www.cde.org.tw/Content/Files/Knowledge/48e6077b-f70c-4e96-8d47-5d808c27f480.pdf)
print cancel